India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization has approved Novo Nordisk's drug Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). This marks the first time a GLP-1 receptor agonist has been approved in India for this specific liver condition.
Why it matters
This approval expands treatment options for patients suffering from fatty liver disease, a condition often linked to obesity and metabolic health.
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication — fatty liver disease.
The report is a straightforward announcement of a regulatory approval based on clinical trial data.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in